Genmab A/S
GMAB · NASDAQ
Bulios Fair Price
$45.65
39.8% upside
Current Price
$32.65
According to Bulios Fair Price, GMAB is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Genmab A/S (GMAB) is a Danish biotechnology company specializing in the research, development, and manufacturing of monoclonal antibodies for the treatment of various types of cancer and immune-related diseases. The company is known for its innovative approaches to therapies and a robust portfolio of therapeutic antibodies undergoing clinical trials. Genmab focuses on collaborations with pharmaceutical partners and leverages its advanced technology to create medicines with the potential to revolutionize the way diseases are treated. Genmab A/S (GMAB) shares might appeal to investors seeking exponential growth in the biotechnology sector.
Sector
Healthcare
Industry
Biotechnology
CEO
Jan van de Winkel
Employees
3,119
Headquarters
Copenhagen
Upcoming events
Earnings
Upcoming earnings report